Papers by Jose Dominguez-escrig
Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488]
European Urology
Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum
European Urology Oncology
![Research paper thumbnail of EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort †[Formula presented] : Under the Auspices of the EAU-ESMO Guidelines Committees](https://attachments.academia-assets.com/93036312/thumbnails/1.jpg)
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidenc... more BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagre...
T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum
European Urology Focus
![Research paper thumbnail of [Active surveillance in prostate cancer and quality of life]](https://a.academia-assets.com/images/blank-paper.jpg)
[Active surveillance in prostate cancer and quality of life]
Archivos espanoles de urologia, 2014
Active surveillance was born as a therapeutic strategy for a well selected group of patients with... more Active surveillance was born as a therapeutic strategy for a well selected group of patients with low risk prostate cancer with the aim to defer or completely avoid the negative impact of secondary effects of curative therapies. Nevertheless, the patient who chooses this treatment does it at the expense of greater anxiety and doubts about the possible progression of the disease. The main psychological features influencing the quality of life of these patients are, on one hand anxiety, due to the uncertainty and fear to disease progression, and on the other hand, the difficult decision making process. Among the factors that seem to influence the election are: urologist's recommendation, effects on urinary function, age and impact of the therapy on sexual function. In the timorous journey walked, it is recommended to apply psycho-educational programs, with the objective of increasing the perceived control and adaptive confrontation. We propose an intervention with 4 group sessions...
Comparing Image Perception of Bladder Tumours in Four Different Storz Professional Image Enhancement System (SPIES) Modalities using the íSPIES App
Journal of endourology / Endourological Society, May 8, 2016
Objectives To evaluate the variation of interpretation of the same bladder urothelium image in di... more Objectives To evaluate the variation of interpretation of the same bladder urothelium image in different Storz Professional Image Enhancement System (SPIES) modalities. SPIES contains a White light (WL), Spectra A (SA), Spectra B (SB), Clara and Chroma (CC) modality. Materials & methods An App for the i-PAD retina was developed to study evaluation of images. A total of 80 images from 20 bladder areas acquired in four modalities were included. 73 participants completed the study. Images were analyzed on differences in delineated tumor margin variation, perceived quality of the image and delineation time. Results A separation between high agreement (n=14), and low agreement (n=6) images was found. In high agreement images, no difference in root mean square (RMS) was found between modalities. In low agreement images, WL (26.5 pix) and SA (33.4 pix) had a higher RMS than CC (18 pix) and SB (21.4 pix). The quality of SPIES modalities images was rated significantly higher. Delineation tim...
Evaluation of the Prenyltransferase Inhibitor AZD3409 in Pre-Clinical Models of Urothelial Carcinoma
European Urology Supplements, 2006
Current urology reports, 2012
Bladder cancer is the most common malignancy of the urinary tract. About 75%-85% of patients pres... more Bladder cancer is the most common malignancy of the urinary tract. About 75%-85% of patients present with non-muscle-invasive bladder cancer (NMIBC). However, patients with pT1 tumors, as well as all those with high-grade disease, make up a subset with a high-risk of recurrence and disease progression. Although still regarded as the gold standard, clinical evidence from contemporary published series clearly demonstrates that transurethral resection of tumor (TUR) is a procedure far from optimal, highlighting its limitations and the need for further diagnostic accuracy. Routine use of a restaging TUR (re-TUR), supported by the American Urological Association and European Association of Urology guidelines, detects residual tumor in a significant number of cases after initial TUR. It provides a more accurate staging of the disease and, consequently, helps to guide its treatment. Recent years have seen rapid development of novel optical techniques aimed to optimize resection. Routine im...
Urologic Oncology: Seminars and Original Investigations, 2013
Introduction: As a urologist, it is common to review a patient above the age of 70 being referred... more Introduction: As a urologist, it is common to review a patient above the age of 70 being referred to a prostate assessments clinic with an elevated PSA. We evaluate the prognosis of these patients clinically as there is no international consensus on the exact PSA cutoff level or a single international guideline as to when these patients should be offered a prostate biopsy. Patients and methods: On receiving ethic committee approval, we recruited 427 consecutive patients aged 70 years and above referred with a PSA of Ն4 ng/ml, from January 1996 to December 2000, into our study. All patients were assessed, examined with a digital rectal examination (DRE) of the prostate, and a subsequent prostate biopsy. We followed up on their histologic diagnosis for up to 10 years and analyzed their outcome. The main outcome measures were disease-free survival and overall survival, stratified according to the PSA level (Յ15 vs. Ͼ15 ng/ml) and DRE findings (normal vs. sbnormal). Results: There was a statistically significant difference in the overall survival (P value Ͻ 0.011) and disease specific survival (P value Ͻ 0.0001) of cancer patients with a PSA was Ͼ15 ng/ml and an abnormal DRE. However, in patients with a PSA Յ15 ng/ml and normal DRE, the incidence of cancer was low and they had no disease-specific or overall survival benefit. Conclusions: A policy of deferring prostate biopsy in patients with a PSA Յ15 ng/ml and normal DRE (Group A) would significantly decrease the need of unnecessary prostate biopsies. Within this group, patients did not have any survival advantage compared with those without cancer. We conclude that up to 20% of the prostate biopsies performed in this age group could have been avoided.
Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study
European Urology Oncology
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
European Urology
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]
European Urology
Ex-vivo confocal fluorescence microscopy for rapid evaluation of renal core biopsy
Minerva Urologica e Nefrologica
European Urology
Background: Although guidelines exist for advanced and variant bladder cancer management, evidenc... more Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Outcome measurements and statistical analysis: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as 70% agreement and 15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Results and limitations: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease. Conclusions: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach. Patient summary: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
Urologic Oncology: Seminars and Original Investigations
World Journal of Urology
Context In recent years, focal therapy has emerged as a treatment option for a selected group of ... more Context In recent years, focal therapy has emerged as a treatment option for a selected group of men with localized prostate cancer. Cryotherapy and high-intensity focused ultrasound (HIFU) are the most investigated types of focal treatment with other options currently under evaluation. Objective The objective of the study was to give a comprehensive overview of six available focal treatment options for prostate cancer with their rationale, delivery mechanism, and outcomes. Information acquisition The SIU ICUD chapter on available Energies to Treat Prostate Cancer was used as a guide to describe the different technologies. For outcomes, a literature search was conducted using PubMed key words including focal therapy, HIFU, cryotherapy, irreversible electroporation, vascular-targeted photodynamic therapy, laser interstitial therapy, radiofrequency ablation, microwave therapy, and their synonyms in MeSH terms. Conclusion Focal therapy appears to have encouraging outcomes on quality of life and urinary and erectile function. For oncological outcomes, it is challenging to fully interpret the outcomes due to heterogeneity in patient selection and shortterm follow-up.
Magnetic resonance imaging as an assessment tool following intervention with an AdVance XP suburethral sling for postprostatectomy urinary incontinence
Neurourology and Urodynamics
The Journal of Urology
We assessed the state of younger AS patients from the analysis Japanese cohort(PRIAS-JAPAN) formi... more We assessed the state of younger AS patients from the analysis Japanese cohort(PRIAS-JAPAN) forming part of the Prostate Cancer Research International: Active Surveillance (PRIAS) study. METHODS: PRIAS-JAPAN started in January 2010. 37 institutions are participating in this study, and the Institutional Review Boards of the participating centers have approved the study protocol. The inclusion criteria for the PRIAS study are as follows: clinical stage T1c/T2, PSA ¼ 10 ng/ml, PSA density (PSAD) < 0.2 ng/ml per milliliter, one or two positive biopsy cores, and Gleason score (GS) ¼ 6 at initial diagnostic biopsy. Pathological reclassification is defined as the deviation of pathological findings on re-biopsy from the inclusion criteria. Patients are recommended active treatment if the PSA doubling time (PSADT) is <3 years (until December 2014) or if reclassification is comfirmed on re-biopsy. Since 2015, PSADT has become a trigger for extra yearly re-biopsy, and patients are not recommended active treatment because of short PSADT (<3 years). In this analysis, we defined re-biopsy at 1-year as 1st re-biopsy and at 4-year biopsy including extra biopsy as 2nd re-biopsy. We compared the clinical outcome and pathological result of re-biopsy between the group of less than 60 years old (young group) and the groups of over 60 years old or more (aged group). RESULTS: Until September 2017, 768 patients were enrolled and 96 were in young group at enrollment. Patients back ground of young group was as follows: Median age was 56, median PSA was 4.9ng/ml. One positive core was in 73 and two positive cores were in 23. T1c were in 92 and T2a were in 4. At enrollment, the prostate volume of young group was significantly smaller than that of older group. However, there is a not significant difference between both group in PSA value and pathological factors. Re-biopsy rate of young group is lower than that of aged group at 1 year(young group vs aged group; 59% vs 77%)and 4 year(39% vs 47%). Although Re-classification rate of 1st rebiopsy is lower in young group(16.3% vs27.7%), that of 2nd re-biopsy was the equivalent of the value in both group(20% vs 22.5%). After one year and five years, both group shows similar AS remaining rate (one year; 84.2vs 85.7%, five years; 42.2 vs 51.7%). 24 patients of young group selected definitive therapy and surgery was the most frequently chosen treatment option. CONCLUSIONS: There is a not significant difference between both group in AS remaining rate. Younger patients tend to avoid re-biopsy but to choose surgery as a definitive therapy.
949: The EGFR-Tyrosine Kinase Inhibitor Gefitinib (‘Iressa’, ZD-1839) as Potential Therapeutic in Bladder Cancer
The Journal of Urology
Uploads
Papers by Jose Dominguez-escrig